| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000134734 |
| P698 | PubMed publication ID | 9605863 |
| P50 | author | Lloyd J. Old | Q1866929 |
| P2093 | author name string | Y T Chen | |
| C S Viars | |||
| K C Arden | |||
| S Tsang | |||
| A D Boyer | |||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 237-40 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Cytogenetics and Genome Research | Q1524623 |
| P1476 | title | Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28 | |
| P478 | volume | 79 |
| Q78385365 | A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved |
| Q33709910 | A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia. |
| Q42505471 | A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant |
| Q60913472 | A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells |
| Q47132018 | Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma |
| Q34795079 | Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. |
| Q36400401 | Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma |
| Q33892059 | CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis |
| Q30829189 | CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis |
| Q28220657 | Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas |
| Q35733359 | Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis |
| Q44011532 | Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. |
| Q28215652 | Cancer/testis antigens: an expanding family of targets for cancer immunotherapy |
| Q34568997 | Cancer/testis antigens: structural and immunobiological properties |
| Q35067995 | Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells |
| Q38780728 | Current status and future prospects of peptide-based cancer vaccines |
| Q36471827 | Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. |
| Q37136357 | Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. |
| Q42235384 | Expression and immunogenicity of NY-ESO-1 in colorectal cancer |
| Q31036179 | Expression of cancer/testis antigens in cutaneous T cell lymphomas |
| Q92933897 | First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors |
| Q28975750 | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
| Q28188712 | Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues |
| Q36768976 | Immunotherapeutic strategies for high-risk bladder cancer |
| Q38034661 | LDH-C4: a target with therapeutic potential for cancer and contraception |
| Q35693584 | Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. |
| Q34221846 | NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma |
| Q36637651 | NY-ESO-1 immunotherapy for multiple myeloma |
| Q51061495 | NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms. |
| Q41821668 | New paths in human cancer serology |
| Q35799353 | Rapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy |
| Q50769076 | Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. |
| Q39912679 | Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells |
| Q84904896 | The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas |
| Q33825170 | The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner |
| Q37788829 | The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease |
| Q35005955 | The use of HLA class I tetramers to design a vaccination strategy for melanoma patients |
| Q36307671 | Toxicities Associated With Adoptive T-Cell Transfer for Cancer |
| Q37635491 | Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy |
| Q36573831 | Use of autoantibodies in breast cancer screening and diagnosis. |
| Q55447676 | [Expression and Clinical Significance of MAGE-C2 in Lung Adenocarcinoma]. |
Search more.